The White House withdrew Heidi Overton's nomination to lead the Food and Drug Administration on Tuesday, one day before the Senate health committee was scheduled to vote on whether to advance it. A White House official confirmed the decision to USA Today; Axios first reported it.
The withdrawal ended a three-month bid that had been in trouble from the start. Overton, a preventive medicine physician and deputy director of the White House Domestic Policy Council, was nominated in August to succeed former commissioner Marty Makary, who resigned in May.
One vote to spare
With Democrats expected to oppose her, Overton needed unanimous Republican support on the 21-member Senate Health, Education, Labor and Pensions Committee. Republicans hold a one-vote edge on the panel, so a single defection would have sunk the nomination.
Committee chairman Bill Cassidy, a Louisiana Republican and a physician, said he remained undecided and had criticized Overton's role in the administration's push to roll back childhood vaccinations. In August, Overton appeared beside Trump as he signed an executive order to cut the number of federally recommended childhood vaccines and split the measles, mumps and rubella shot into three separate doses.
“She is known to take on the HARDEST issues, and bring me solutions that work best for the Country.”— President Donald Trump, announcing Overton's nomination in August
Objections from every direction
Overton's record drew fire from several directions at once. Democrats scrutinized her anti-abortion views — she has called the Supreme Court's 2022 decision overturning Roe v. Wade “a huge victory for life” — and her criticism of looser rules for dispensing the abortion pill mifepristone. The FDA is conducting a safety review of the drug that is due to conclude by March 2027.
She also drew fire over vaping, defending the FDA's May authorization of fruit-flavored vapes at her September confirmation hearing, and supporters of Health Secretary Robert F. Kennedy Jr.'s “Make America Healthy Again” movement criticized her corporate ties. An advocacy group even campaigned against her under the nickname “Heidi Vaperton.”
What happens next
The White House has not confirmed a replacement. According to two people familiar with the matter, the administration is weighing Sen. Roger Marshall of Kansas, a former obstetrician who recently lost his reelection bid, as the next nominee.
Until a new nominee is named and confirmed, the FDA remains under acting commissioner Kyle Diamantas, the deputy commissioner for food. The agency has lost more than 4,500 staff over the past year amid workforce cuts ordered across the health department — and the search for a permanent leader starts over, with the committee vote scrapped and the vacancy now six months old.


